Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 229

1.

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.

Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, Chen D, Becker JC.

Ann Rheum Dis. 2007 Feb;66(2):228-34. Epub 2006 Aug 25.

PMID:
16935912
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Li T, Ge Z, Becker JC, Westhovens R.

Ann Intern Med. 2006 Jun 20;144(12):865-76.

PMID:
16785475
[PubMed - indexed for MEDLINE]
3.

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.

Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, Li T, Schmidely N, Le Bars M, Dougados M.

Ann Rheum Dis. 2008 Apr;67(4):547-54. Epub 2007 Oct 5.

PMID:
17921185
[PubMed - indexed for MEDLINE]
4.

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators.

Lancet. 2004 Feb 28;363(9410):675-81.

PMID:
15001324
[PubMed - indexed for MEDLINE]
5.

Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH; Paediatric Rheumatology INternational Trials Organization; Pediatric Rheumatology Collaborative Study Group.

Lancet. 2008 Aug 2;372(9636):383-91. doi: 10.1016/S0140-6736(08)60998-8. Epub 2008 Jul 14.

PMID:
18632147
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.

Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Saldate C, Li T, Aranda R, Becker JC, Lin C, Cornet PL, Dougados M.

Ann Rheum Dis. 2008 Aug;67(8):1096-103. Epub 2007 Nov 29.

PMID:
18055472
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial.

Kremer JM, Russell AS, Emery P, Abud-Mendoza C, Szechinski J, Westhovens R, Li T, Zhou X, Becker JC, Aranda R, Peterfy C, Genant HK.

Ann Rheum Dis. 2011 Oct;70(10):1826-30. doi: 10.1136/ard.2010.139345.

PMID:
21893583
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.

Arthritis Rheum. 2004 Feb;50(2):353-63.

PMID:
14872476
[PubMed - indexed for MEDLINE]
Free Article
9.

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.

Genovese MC, Schiff M, Luggen M, Le Bars M, Aranda R, Elegbe A, Dougados M.

J Rheumatol. 2012 Aug;39(8):1546-54. doi: 10.3899/jrheum.111531. Epub 2012 Jul 15.

PMID:
22798265
[PubMed - indexed for MEDLINE]
10.

Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison.

Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, Pavelka K, Sambrook PN, Smolen JS, Wajdula J, Fatenejad S; Etanercept European Investigators Network (Etanercept Study 309 Investigators).

Ann Rheum Dis. 2006 Oct;65(10):1357-62. Epub 2006 Apr 10.

PMID:
16606651
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B.

Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17.

PMID:
23332236
[PubMed - indexed for MEDLINE]
12.

Etanercept: a review of its use in rheumatoid arthritis.

Jarvis B, Faulds D.

Drugs. 1999 Jun;57(6):945-66. Review.

PMID:
10400407
[PubMed - indexed for MEDLINE]
13.

Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.

Culy CR, Keating GM.

Drugs. 2002;62(17):2493-537. Review.

PMID:
12421111
[PubMed - indexed for MEDLINE]
14.

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ.

N Engl J Med. 1999 Jan 28;340(4):253-9.

PMID:
9920948
[PubMed - indexed for MEDLINE]
Free Article
15.

Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations.

Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ.

Arthritis Rheum. 2003 Jun;48(6):1493-9.

PMID:
12794815
[PubMed - indexed for MEDLINE]
Free Article
16.

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis.

Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhães C, Chavez-Corrales J, Huemer C, Kivitz A, Blanco FJ, Foeldvari I, Hofer M, Horneff G, Huppertz HI, Job-Deslandre C, Loy A, Minden K, Punaro M, Nunez AF, Sigal LH, Block AJ, Nys M, Martini A, Giannini EH; Paediatric Rheumatology International Trials Organization and the Pediatric Rheumatology Collaborative Study Group.

Arthritis Rheum. 2010 Jun;62(6):1792-802. doi: 10.1002/art.27431.

PMID:
20191582
[PubMed - indexed for MEDLINE]
Free Article
17.
18.

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.

Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M.

N Engl J Med. 2005 Sep 15;353(11):1114-23. Erratum in: N Engl J Med. 2005 Nov 24;353(21):2311.

PMID:
16162882
[PubMed - indexed for MEDLINE]
Free Article
19.

A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study.

Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M Jr.

J Formos Med Assoc. 2004 Aug;103(8):618-23.

PMID:
15340661
[PubMed - indexed for MEDLINE]
20.

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME.

Ann Intern Med. 1999 Mar 16;130(6):478-86.

PMID:
10075615
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk